Argus research initiates equity research report coverage on bioaffinity technologies, inc. (nasdaqcm: biaf)

New york, dec. 19, 2022 /prnewswire/ -- argus research, an independent investment research firm, has launched equity research report coverage on bioaffinity technologies, inc. (nasdaqcm: biaf) click here to view full argus equity research report. company highlights: excerpts (as conveyed by argus analyst steve silver) include: biaf:  a potential advance in the early detection of cancer in our view, bioaffinity is well positioned to establish its cypath® lung test as a cost-effective, non-invasive tool to aid in the early detection of lung cancer, which is among the most common and deadly forms of cancer.
BIAF Ratings Summary
BIAF Quant Ranking